文献速递骨软组织肉瘤与黑色素瘤

不可切除或转移性胃肠道间质瘤患者的十年无进展生存和总生存:欧洲癌症研究与治疗组织、意大利肉瘤小组和澳大拉西亚胃肠道试验小组关于伊马替尼两种剂量水平的组间III期随机试验的长期分析

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
PubMed 文献 · J Clin Oncol · 2017-03-31

该随机III期试验纳入946例晚期CD117阳性胃肠道间质瘤患者,比较伊马替尼400 mg/d与800 mg/d。中位随访10.9年,两组中位无进展生存期分别为1.7年和2.0年(HR 0.91,P=0.18),中位总生存期均为3.9年,10年无进展生存率分别为9.5%和9.2%,10年总生存率分别为19.4%和21.5%。

要点

  • 伊马替尼400 mg与800 mg组中位无进展生存期分别为1.7年和2.0年(HR 0.91,P=0.18)。
  • 两组中位总生存期均为3.9年,10年总生存率分别为19.4%和21.5%。
  • 年龄<60岁、体力状态0、最大病灶较小和KIT外显子11突变是生存超过10年的显著预后因素。

核心结论

  • 在中位随访10.9年的长期分析中,约6%的患者长期无进展,13%的患者长期存活。
  • 临床预后因素中,仅体力状态、KIT突变和最大病灶大小预测长期结局,可能反映较低的疾病负荷。
  • 基因组和/或免疫分析可能有助于理解长期生存,解决继发性耐药仍是治疗挑战。

研究设计与样本

  • 随机III期试验,纳入来自13个国家56个机构的946例晚期CD117阳性胃肠道间质瘤患者,随机接受伊马替尼400 mg/d或800 mg/d。
  • 400 mg组患者在疾病进展后允许交叉至800 mg。
  • 2001年2月至2002年2月期间入组,中位年龄60岁(范围18至91岁),中位随访10.9年。

主要发现

  • 400 mg组与800 mg组的中位无进展生存期分别为1.7年和2.0年(HR 0.91,P=0.18)。
  • 两组中位总生存期均为3.9年。
  • 400 mg组与800 mg组的估计10年无进展生存率分别为9.5%和9.2%。
  • 400 mg组与800 mg组的估计10年总生存率分别为19.4%和21.5%。
  • 多变量分析中,年龄<60岁、体力状态0(对比≥1)、最大病灶较小和KIT外显子11突变是生存超过10年的显著预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods Eligible patients with advanced CD117-positive GIST from 56 institutions in 13 countries were randomly assigned to receive either imatinib 400 mg or 800 mg daily. Patients on the 400-mg arm were allowed to cross over to 800 mg upon progression. Results Between February 2001 and February 2002, 946 patients were accrued. Median age was 60 years (range, 18 to 91 years). Median follow-up time was 10.9 years. Median progression-free survival times were 1.7 and 2.0 years in the 400- and 800-mg arms, respectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treatment arms. The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively. At multivariable analysis, age (< 60 years), performance status (0 v ≥ 1), size of the largest lesion (smaller), and KIT mutation (exon 11) were significant prognostic factors for the probability of surviving beyond 10 years. Conclusion This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic and/or immune profiling could help understand long-term survivorship. Addressing secondary resistance remains a therapeutic challenge.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Casali PG, Zalcberg J, Le Cesne A, et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol. 2017. PMID: 28362562. doi:10.1200/JCO.2016.71.0228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。